Where is PREDICT located?

PREDICT is headquartered in London, United Kingdom.

Is PREDICT a funded company?

PREDICT is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does PREDICT rank among its competitors?

PREDICT ranks 35th amongst 39 active competitors, of which 11 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Vizzhy, which secured an undisclosed amount in Aug, 2025.

Who are the top competitors of PREDICT?

PREDICT's top competitors include Microba, Seed and OptiBiotix Health. Among them, Vizzhy secured the most recent funding round in August, 2025.

PREDICT - 2026 Company Profile & Competitors

Company Details

Provider of a platform for personalized analysis and interpretation of a patient’s gut bacteria. The company uses sequencing technology to diagnose the gut microbiome, and then a person feeds data on his or her food habit for a period of two weeks. The application thus by analyzing the data, helps in providing health advice on lifestyle and nutritional changes.

Website: predict.study
Social
Part Of

Key Metrics

Founded Year

2016

Location

London, United Kingdom

Stage

Unfunded

Ranked

35^th among 39 active competitors

Similar Companies

Microba & 51 more

View PREDICT's full profile

PREDICT has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PREDICT include Microba, Seed and OptiBiotix Health. Here is the list of Top 10 competitors of PREDICT, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Microba 2017, Brisbane (Australia), Public	Developer of microbiome-based drug discovery platform	$2.85M	Macrogen, YMF Investments & 6 others	63/100
2nd	Seed 2016, Los Angeles (United States), Series A	Developer of synbiotics for simulating gut microbiome	$40.6M	Greycroft, BoxGroup & 26 others	57/100
3rd	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Mercia & 2 others	55/100
4th	Azitra 2014, Farmington (United States), Public	Developer of micriobiome based therapeutics solution for treating skin atopic dermatitis or eczema	$37.4M	Bios Partners, Connecticut Innovations & 8 others	54/100
5th	BiomeSense 2018, Chicago (United States), Seed	Developer of AI-enabled technology platform for microbiome data generation and analysis	$8.43M	Bluestein Ventures, IndieBio & 11 others	46/100
6th	Vizzhy 2019, Austin (United States), Seed	Provider of multi omics based metabolic signature program and solutions for metabolic health issues	-	Genie Healthcare	44/100
7th	Mybacs 2018, Baar (Switzerland), Series A	Manufacturer of probiotic products for digestion	$5.92M	Global Founders Capital, naturalX Health Ventures ... & 7 others	44/100
8th	uBiome 2012, San Francisco (United States), Deadpooled	Provider of sequence dataset of human microbiome	$110M	8VC, Andreessen Horowitz & 26 others	44/100
9th	BIOMES 2017, Wildau (Germany), Seed	Provider of genetic testing serivces for gut health diagostics	$2.17M	Yabeo, Kontor 4 Verwaltungs GmbH & 19 others	44/100
10th	Carbiotix 2014, Lund (Sweden), Funding Raised	Developer of prebiotic ingredients and consumer products	-	EIC Fund, Europa	41/100
35th	PREDICT 2016, London (United Kingdom), Unfunded	Provider of a platform for personalized analysis and interpretation of a patient’s gut bacteria	-	-	24/100